Timing is everything: new trial seeks to boost lung cancer treatment by rescheduling immunotherapy
NCT ID NCT07190027
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This clinical trial is testing whether giving immunotherapy a few days after chemotherapy, instead of on the same day, can improve outcomes for people with advanced non-small cell lung cancer. The study will enroll 246 adults and compare three different timing schedules, including a personalized approach based on daily immune monitoring. The goal is to see if adjusting the timing can shrink tumors more effectively and delay disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PD-1 inhibitor (e.g., sintilimab, pembrolizumab, camrelizumab) combined with platinum-based chemotherapy
- What this could lead to
- If successful, this could show that timing immunotherapy a few days after chemotherapy improves tumor shrinkage and delays progression in advanced lung cancer.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small sample, so results may not be conclusive. The personalized timing approach is complex and may not work better than standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart cancer therapy: tailoring lung cancer treatment with a simple blood test
- New drug cocktail targets tough lung cancer
- Blood test could speed up lung cancer treatment decisions
- New drug duo takes on advanced lung cancer
- Could a common antioxidant boost chemo for advanced lung cancer?
- Lung cancer surgery risks under the microscope: 1,000 patients studied